March 26, 2010

New Inhaled Cystic Fibrosis Therapy

here may be relief on the horizion for Cystic Fibrosis (CF) patients with pseudomonas aeruginosa. As of last month, the Foster City, California biopharmaceutical company, Gilead Sciences Inc. moved forward with its Cayston. The U.S. FDA finally cleared the release of the generically Aztreonam. The Aztreonam or “Azactam” is a drug that has traveled leaps and bounds since its acceptance back in 1986. Cayston is inhaled 3 times a day and acts similarly to penicillin to improve respiratory symptoms for those CF patients with lower immunity that have contracted pseudomonas aeruginosa.

Cayston was actually cleared for marketing in Australia back in January. It received a clearance in Canada and the European Union with stipulations even earlier back in September of 2009.